menu
Investors & Media

Press Releases

Press Releases

Keyword Search

Jun 14, 2021
Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine
Jun 10, 2021
Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting
Jun 02, 2021
Ionis announces changes to its board of directors at annual meeting of stockholders
May 26, 2021
Ionis to present at upcoming investor conferences
May 06, 2021
Ionis to present at upcoming investor conferences
May 05, 2021
Ionis to host 2021 virtual annual meeting of stockholders
May 05, 2021
Ionis reports first quarter 2021 financial results and recent business achievements
Apr 21, 2021
Ionis to hold first quarter 2021 financial results webcast
Apr 20, 2021
Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
Apr 08, 2021
Ionis prices private placement of convertible senior notes
Apr 06, 2021
Ionis announces proposed private placement of convertible notes
Apr 05, 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Mar 29, 2021
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
Mar 26, 2021
Ionis to present at upcoming investor conferences
Mar 22, 2021
Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)
Mar 01, 2021
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
Feb 24, 2021
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
Feb 19, 2021
Ionis to present at upcoming investor conferences
Feb 11, 2021
Ionis to hold 2020 financial results webcast
Jan 07, 2021
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
Jan 05, 2021
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
Load More »